NASDAQ:PCVX Vaxcyte (PCVX) Stock Price, News & Analysis $111.58 -0.52 (-0.46%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$110.48▼$115.4450-Day Range$70.52▼$112.1052-Week Range$44.20▼$119.27Volume2.35 million shsAverage Volume833,799 shsMarket Capitalization$12.14 billionP/E RatioN/ADividend YieldN/APrice Target$131.83 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Vaxcyte alerts: Email Address Vaxcyte MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside18.2% Upside$131.83 Price TargetShort InterestBearish10.33% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.45Based on 42 Articles This WeekInsider TradingSelling Shares$7.27 M Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($4.33) to ($4.49) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.49 out of 5 starsMedical Sector658th out of 910 stocksBiological Products, Except Diagnostic Industry107th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingVaxcyte has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageVaxcyte has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Vaxcyte's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted10.33% of the outstanding shares of Vaxcyte have been sold short.Short Interest Ratio / Days to CoverVaxcyte has a short interest ratio ("days to cover") of 15.9, which indicates bearish sentiment.Change versus previous monthShort interest in Vaxcyte has recently decreased by 2.26%, indicating that investor sentiment is improving. Previous Next 0.0 Dividend Strength Dividend YieldVaxcyte does not currently pay a dividend.Dividend GrowthVaxcyte does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for PCVX. Previous Next 2.5 News and Social Media Coverage News SentimentVaxcyte has a news sentiment score of 0.45. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 42 news articles for Vaxcyte this week, compared to 4 articles on an average week.Search Interest4 people have searched for PCVX on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Vaxcyte to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Vaxcyte insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $7,271,218.00 in company stock.Percentage Held by InsidersOnly 3.10% of the stock of Vaxcyte is held by insiders.Percentage Held by Institutions96.78% of the stock of Vaxcyte is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Vaxcyte's insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Vaxcyte are expected to decrease in the coming year, from ($4.33) to ($4.49) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Vaxcyte is -26.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Vaxcyte is -26.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioVaxcyte has a P/B Ratio of 8.56. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Vaxcyte's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Porter & CompanyThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming.So go here now to read my new report The Big AI Die-Up… while you still can. About Vaxcyte Stock (NASDAQ:PCVX)Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.Read More PCVX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart PCVX Stock News HeadlinesSeptember 6 at 8:35 AM | insidertrades.comInsider Selling: Vaxcyte, Inc. (NASDAQ:PCVX) SVP Sells 5,000 Shares of StockAugust 28, 2024 | insidertrades.comGrant Pickering Sells 15,000 Shares of Vaxcyte, Inc. (NASDAQ:PCVX) StockSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 7 at 6:45 AM | americanbankingnews.comVaxcyte, Inc. (NASDAQ:PCVX) SVP Sells $538,350.00 in StockSeptember 6 at 7:07 PM | morningstar.comVaxcyte's stock dips after biotech completes $1.42 billion stock offeringSeptember 6 at 7:07 PM | markets.businessinsider.comVaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional SharesSeptember 6 at 7:07 PM | seekingalpha.comVaxcyte: Stunning PCV Data Readout Suggests Vaccine Maker Is A Strong BuySeptember 6 at 4:05 PM | globenewswire.comVaxcyte Announces Closing of $1.5 Billion Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional SharesSeptember 7, 2024 | Paradigm Press (Ad)Kamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppet masters are planning this dirty election move… September 6 at 5:01 AM | americanbankingnews.comBank of America Increases Vaxcyte (NASDAQ:PCVX) Price Target to $140.00September 6 at 2:33 AM | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Sees Large Volume Increase Following Analyst UpgradeSeptember 6 at 1:07 AM | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Shares Gap Up After Analyst UpgradeSeptember 5 at 7:36 AM | markets.businessinsider.comVaxcyte’s VAX-31 Vaccine Poised to Dominate PCV Market: A Comprehensive Buy Rating AnalysisSeptember 5 at 3:29 AM | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Price Target Increased to $129.00 by Analysts at Jefferies Financial GroupSeptember 5 at 2:57 AM | americanbankingnews.comVaxcyte (NASDAQ:PCVX) PT Raised to $160.00 at BTIG ResearchSeptember 5 at 1:22 AM | reuters.comVaxcyte to raise $1.3 bln from shares, warrants sale after stock's surge to record highSeptember 4 at 11:58 PM | globenewswire.comVaxcyte Announces Pricing of $1.3 Billion Public OfferingSeptember 4 at 3:27 AM | americanbankingnews.comVaxcyte (NASDAQ:PCVX) Price Target Raised to $140.00 at Needham & Company LLCSee More Headlines Receive PCVX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Vaxcyte and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/06/2024Today9/07/2024Next Earnings (Estimated)11/04/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PCVX CUSIPN/A CIK1649094 Webwww.vaxcyte.com Phone650-837-0111FaxN/AEmployees160Year FoundedN/APrice Target and Rating Average Stock Price Target$131.83 High Stock Price Target$160.00 Low Stock Price Target$69.00 Potential Upside/Downside+18.2%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage7 Analysts Profitability EPS (Most Recent Fiscal Year)($4.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-402,270,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-30.07% Return on Assets-28.08% Debt Debt-to-Equity RatioN/A Current Ratio17.88 Quick Ratio17.88 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$13.04 per share Price / Book8.56Miscellaneous Outstanding Shares108,795,000Free Float105,422,000Market Cap$12.14 billion OptionableOptionable Beta0.97 A Guide To High-Short-Interest StocksMarketBeat's analysts have just released their top five short plays for September 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Grant E. Pickering M.B.A. (Age 56)Co-Founder, CEO & Director Comp: $1.13MMr. Andrew L. Guggenhime M.B.A. (Age 56)President & CFO Comp: $820.81kMr. James Wassil M.B.A. (Age 55)M.S., Executive VP & COO Comp: $521.05kMr. Mikhail Eydelman J.D. (Age 42)Senior VP, General Counsel, Chief Compliance Officer & Corporate Secretary Comp: $684.62kDr. Ashish Khanna M.B.A. (Age 52)Ph.D., Co-Founder Dr. Jeff Fairman Ph.D. (Age 60)Co-Founder & VP of Research Ms. Elvia Cowan (Age 51)Senior VP of Finance & Principal Accounting Officer Ms. Janet GraesserSenior Vice President of Corporate Communications & Investor RelationsMs. Whitney JonesChief People OfficerMr. Paul W. Sauer M.B.A. (Age 63)Senior Vice President of Process Development & Manufacturing Comp: $608.96kMore ExecutivesKey CompetitorsForma TherapeuticsNASDAQ:FMTXScholar RockNASDAQ:SRRKEditas MedicineNASDAQ:EDITSangamo TherapeuticsNASDAQ:SGMOAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsJim WassilSold 10,000 sharesTotal: $1.12 M ($111.93/share)Elvia CowanSold 5,000 sharesTotal: $538,350.00 ($107.67/share)Clearbridge Investments LLCBought 186,141 shares on 8/27/2024Ownership: 0.171%Grant PickeringSold 15,000 sharesTotal: $1.18 M ($78.98/share)Truist Financial CorpSold 674 shares on 8/21/2024Ownership: 0.006%View All Insider TransactionsView All Institutional Transactions PCVX Stock Analysis - Frequently Asked Questions How have PCVX shares performed this year? Vaxcyte's stock was trading at $62.80 at the beginning of 2024. Since then, PCVX stock has increased by 77.7% and is now trading at $111.58. View the best growth stocks for 2024 here. How were Vaxcyte's earnings last quarter? Vaxcyte, Inc. (NASDAQ:PCVX) posted its earnings results on Tuesday, August, 6th. The company reported ($1.10) EPS for the quarter, missing the consensus estimate of ($0.98) by $0.12. When did Vaxcyte IPO? Vaxcyte (PCVX) raised $210 million in an initial public offering on Friday, June 12th 2020. The company issued 14,000,000 shares at a price of $14.00-$16.00 per share. BofA Securities, Jefferies and Evercore ISI acted as the underwriters for the IPO and Cantor and Needham & Company were co-managers. Who are Vaxcyte's major shareholders? Vaxcyte's top institutional shareholders include Darwin Global Management Ltd. (1.86%), Driehaus Capital Management LLC (1.73%), Perceptive Advisors LLC (1.67%) and Fred Alger Management LLC (1.17%). Insiders that own company stock include Grant Pickering, Jeff Fairman, Jim Wassil, Andrew Guggenhime, Mikhail Eydelman, Paul Sauer, Elvia Cowan, Halley E Gilbert and Heath Lukatch. View institutional ownership trends. How do I buy shares of Vaxcyte? Shares of PCVX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Vaxcyte own? Based on aggregate information from My MarketBeat watchlists, some other companies that Vaxcyte investors own include NVIDIA (NVDA), Twilio (TWLO), Boeing (BA), Overstock.com (OSTK), Pure Storage (PSTG), QUALCOMM (QCOM) and Riot Platforms (RIOT). This page (NASDAQ:PCVX) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxcyte, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxcyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PCVX Stock Alerts